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Basic Science
Research Report

Identification of an epidermal keratinocyte AMPA
glutamate receptor involved in dermatopathies
associated with sensory abnormalities
David Cabañeroa,b, Takeshi Iriec, Marta Celorrioa, Christopher Trousdalea, David M. Owensd,e, David Virleyf,
Phillip J. Albrechtg, Michael J. Caterinah, Frank L. Riceg, Jose A. Moróna,i,*
Abstract
Introduction: Epidermal keratinocytes are increasingly recognized as active participants in the sensory transduction of itch and
pain, processes known to involve primary afferent glutamatergic neurons. However, the role of keratinocyte glutamate signaling in
sensory functioning is not fully understood. Here, we present the observation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid–type glutamate receptors (AMPARs) in epidermal keratinocytes.
Methods: Immunohistochemical and in situ hybridization analyses were conducted to assess the expression of AMPAR subunits in
epidermal keratinocytes in mouse and human skin samples, and in organotypic cultures of human keratinocytes. In addition,
reverse transcription PCR further confirmed the expression of GluA4-containing AMPAR in epidermal keratinocytes.
Results: We found prominent immunolabeling for the GluA4 subunit of AMPAR in keratinocytes of glabrous and hairy skin of mouse
epidermis, as well as in human epidermal keratinocytes. Reverse transcription PCR confirmed Gria4 transcript expression in epidermal
mouse keratinocytes. In addition, expression of GRIA4 mRNA was confirmed in epidermal human keratinocytes by in situ hybridization.
Immunohistochemical studies conducted in human skin biopsies from patients with atopic dermatitis and postherpetic neuralgia
demonstrate that keratinocyte expression of GluA4 can be altered under pathological conditions. Moreover, a decrease of GluA4
expression was observed in organotypic cultures of human keratinocytes after direct application of algogenic agents.
Conclusion: We provide evidence that GluA4-containing AMPARs are expressed in epidermal keratinocytes, that human pruritic
and painful dermatopathologies have alterations in the keratinocyte expression levels of GluA4-containing AMPAR, and that itchand pain-producing substances can directly regulate their production in keratinocytes.
Keywords: Keratinocytes, AMPAR, Glutamate, Pain

1. Introduction
The epidermis, the outermost layer of the skin, constitutes a critical
barrier between our internal and external environments, participates
in thermoregulation and innate immunity, and is innervated by
primary afferent neurons that transmit sensory information including
touch, itch, and pain.22,43 Keratinocytes are the most abundant cell
type in the epidermis, and exhibit direct responsiveness to a wide

range of physical and chemical stimuli.38 They are also located in
close physical proximity to the peripheral intraepidermal nerve fiber
(IENF) termini of C- and Ad-type fibers, and peptidergic termini can
release a host of neurochemical mediators on stimulation.1
Accordingly, a growing body of data suggest the existence of
reciprocal interactions between keratinocytes and epidermal
sensory nerve termini.33,36 However, the ability of keratinocytes to
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respond to classical neurotransmitters and other intercellular
signaling molecules is incompletely understood, as is the role of
keratinocytes in pathological sensory states.
In the central nervous system, glutamate is the main excitatory
neurotransmitter, and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid–type glutamate receptors (AMPARs) are the
primary excitatory ion channels for fast neurotransmission
across synapses. A functional AMPAR is a tetramer consisting
of dimers assembled from 4 possible protein subunits: GluA1,
GluA2, GluA3, and GluA4,37,48 which are encoded by the genes
Gria1, Gria2, Gria3, and Gria4 (GRIA1-4 in humans). Although
expression of AMPAR has been extensively studied in the
central nervous system,48 they have also been observed in
peripheral nerves, where they are up-regulated in painful
conditions.10,11 These AMPARs have been described to be
functional in in vivo pharmacological experiments, wherein
activation and inhibition produce pronociceptive and antinociceptive effects, respectively.19,53
Prompted by our recent findings showing that spinal cord
GluA4-containing AMPAR and C-fibers innervating the skin are
involved in opioid-induced pain,8,24 we sought to explore in greater
detail GluA4 AMPAR expression in the primary afferents innervating the glabrous skin of the mouse. Unexpectedly, we found
prominent GluA4 immunolabeling (GluA4-IL) in epidermal mouse
keratinocytes which was confirmed by detecting GluA4 mRNA by
reverse transcription PCR (RT-PCR) of fluorescence-activated cell
sorting (FACS)-isolated mouse keratinocytes. Immunohistochemical and in situ hybridization analyses also revealed GluA4
expression in keratinocytes in human skin. Moreover, we
observed an increase in keratinocyte GluA4 expression in skin
biopsies from patients afflicted with atopic dermatitis (AD), while
a decrease in GluA4 was observed in postherpetic neuralgia
(PHN).25,30,31,35 Furthermore, a decrease of GluA4 expression
occurred in organotypic cultures of human keratinocytes treated
with algogenic agents. Collectively, this study documents for the
first time the expression and regulation of AMPAR in epidermal
keratinocytes, and suggests a critical role for GluA4 AMPAR in 2
clinical conditions involving chronic itch and pain.

(Thermo Scientific, Waltham, MA) and were thaw mounted onto
Fisherbrand Superfrost Plus microscope slides (Fisher Scientific,
Pittsburgh, PA). Slides with sections were kept at 280˚C until use.
2.3. Immunofluorescence microscopy
Samples were permeabilized and blocked using 5% normal goat
serum/Triton X-100 (NGST) applied directly over the microscope
slide for one hour. Five percent NGST was made in PBS
containing 0.3% Triton X-100 and 5% normal goat serum or 5%
normal donkey serum (Sigma-Aldrich). After permeabilization,
samples were incubated with primary antibody overnight in 1%
NGST, then washed 3 times in fresh PBS (5 min/wash). After 1
hour incubation with the secondary antibody in 1% NGST, the
slides were washed again 5 times (10 min/wash), and extra-fine
coverslips (Fisherfinest, Premium Cover Glass; Fisher Scientific
Pittsburgh, PA) were mounted using Fluoromount G mounting
media (SouthernBiotech, Birmingham, AL). Samples were
visualized using an Eclipse Ti confocal microscope (Leica
Microsystems Inc., Buffalo Grove, IL).
2.4. Human newborn foreskin samples
Samples were kindly provided by the Cell and Tissue Kinetics Core
of the Skin Disease Research Center at Columbia University
Medical Center (New York) and also were obtained from St Louis
Children’s Hospital at Washington University School of Medicine (St
Louis). The foreskins were collected from routine circumcisions
performed on neonates at the New York-Presbyterian/Weill Cornell
Medical Center (New York, NY) and Children’s Hospital in St Louis,
MO. Samples were unfixed and cryoembedded in OCT compound.
2.5. Fluorescence-activated cell sorting

Eight to 9-week-old C57BL/6 male mice were used. Protocols
were approved by the Institutional Animal Care and Use
Committee at Columbia University in New York, and Washington
University in St Louis and met the guidelines of the National
Institutes of Health’s Guide for the Care and Use of Laboratory
animals (Department of Health, Education, and Welfare publication no. 85-23, revised 1985, USA).

Primary adult epidermal keratinocytes were isolated from the dorsal
skin of 8- to 9-week-old mice as previously described.39 Freshly
isolated epidermal keratinocytes were suspended in 1% bovine
serum albumin (BSA)-PBS and stained with phycoerythrin (PE)conjugated CD49f-Integrin a6, fluorescein isothiocyanate (FITC)conjugated Ly-6A/E (Sca-1), and allophycocyanin (APC) conjugated
CD34 antibodies (see below for details regarding dilutions). After
washing, cells were stained with 49,6-Diamidino-2-phenylindole
dihydrochloride (DAPI) and then subjected to FACS analysis using
a FACS Aria sorter and FACS DiVa 4.1 software (BD Biosciences,
San Jose, CA). In all cases, cells flew under 30 psi pressure through
a 100 mm nozzle. After eliminating DAPI-positive dead cells, FITC,
APC, and PE signals were collected through 530/30, 660/20, and
576/26 nm band-pass filters, respectively. Viable a6-positive cells
(PE1) were identified and further gated based on their surface
expression of CD34 (APC1) and the absence of Sca-1 (FITC2).

2.2. Mouse tissue preparation for immunofluorescence

2.6. Antibodies

Glabrous skin from the hind paw and hairy skin from the back of
the mouse were depilated with Surgi Cream-Extra Gentle for Face
(Ardell, Los Angeles, CA) and removed by blunt-dissection. Skin
pieces were spread on an index card with the epidermal surface
up, fixed in 4% paraformaldehyde (PFA, Sigma-Aldrich, Saint
Louis, MO) for 20 minutes, washed 3 times in phosphate-buffered
saline (PBS) for 5 minutes/wash, then sunk in 30% sucrose in PBS
for 24 hours. The skin was removed, embedded in Tissue-Tek
optimum cutting temperature (OCT) compound (Sakura Finetek,
Torrance, CA), and frozen. Samples were cut in a cross-sectional
plane at 25 mm thicknesses using a Microm HM 525 Cryostat

The following primary antibodies were used and combined
according to species compatibility: rabbit anti-GluA4C, targeting
the C-terminus of GluA4 (1:250, #AB1508; EMD Millipore,
Billerica, MA), guinea pig anti–GluA4N, targeting the N-terminus
of GluA4 (1:50 for immunohistochemistry #GluA4N-GP-Af640;
Frontier Institute Co, Ltd, Hokkaido, Japan), Alexa647conjugated rat anti–CD34 (1:50 for immunohistochemistry; 1:
100 for FACS, #560233; BD Biosciences, San Diego, CA), PEconjugated rat anti–CD49f-integrin a6 (1:100, #555736; BD
Biosciences), FITC-conjugated rat anti–Ly-6A/E (Sca-1) (1:100,
#11-5981-81; BD Bioscience), rabbit anti–Loricrin (1:1000,

2. Methods
2.1. Animals
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#PRB-145P; BioLegend, Dedham, MA), rabbit anti–thymic
stromal lymphopoietin (TSLP) (1:250, #ab47943; Abcam Inc,
Cambridge, MA). Alexa Fluor–conjugated secondary antibodies
were all obtained from Invitrogen-Molecular Probes (Waltham,
MA), and used at 1:1000 (#A11008 Alexa Fluor 488 goat
anti–rabbit (H1L), #A21450 Alexa Fluor 647 goat anti–guinea
pig, and #A11005 Alexa Fluor 594 goat anti–mouse (H1L)). In
addition to validation by mRNA expression, IL experimental
controls included omission of primary antibodies.
2.7. Mouse keratinocyte reverse transcription polymerase
chain reaction
Total RNA was harvested from 2.5 to 9 3 106 cells of interest by
TRIzol (Life Technologies, Waltham, MA)/chloroform extraction
with an RNeasy kit (Qiagen, Valencia, CA). RNA was quantitated
using a Nanodrop (ND-1000 Thermo Scientific), and PCR
reactions were prepared with 25 ng/12.5 mL OneStep (Qiagen
#210210) RT-PCR reaction using oligos from IDT DNA with
the following sequences (59–.39): Gapdh_ex2-F ATGGTGAA
GGTCGGTGTGA, Gapdh_ex3-R TTTGATGTTAGTGGGGTCTCG,
CD34_ex1-F GCTCTCTGCCTGATGAGTCTG, CD34_ex3-R CCT
TAATGGCACTCGGAGC, Gria4_ex18-F GAGTGCCTTGAGCCT
GAGC, and Gria4_ex19-R GGTAGGTCCGATGCAATGAC. All
PCR oligos were designed to span introns to avoid amplification
of contaminating genomic DNA. The RT-PCR strategy for Gria4
followed this scheme: RT with 50˚C 30 minutes and deactivation at
95˚C 15 minutes, followed directly by touch-down PCR with initial
cycle conditions of 94˚C 30 seconds, 68˚C 30 seconds, 72˚C 20
seconds, with annealing temperatures decremented 1˚C/cycle to
a low of 60˚C, followed by 30 more amplification cycles with 60˚C
annealing, and a 72˚C 10 minutes final extension step. Gapdh and
CD34 amplifications were performed without touchdown, using the
following scheme: RT with 50˚C 30 minutes and deactivation at
95˚C 15 minutes, followed directly by PCR with cycle conditions of
94˚C 30 seconds, 54˚C 30 seconds, 72˚C 30 seconds, and a 72˚C
final extension step. PCR products were separated on a 1.5%
agarose/TAE gel, and bands of interest were excised and purified
with a Qiaquick gel extraction kit (Qiagen #28704). Recovered PCR
products were quantitated by Nanodrop (Thermo Scientific,
Wilmington, DE), and Sanger sequenced. Sequence AB1 files
were visualized with 4Peaks software (Mek&Tosj.com, Amsterdam,
the Netherlands).
2.8. Human skin biopsies
Potential alterations in GluA4, TSLP, and Loricrin expression were
assessed by immunofluorescence in skin biopsies from human
patients afflicted with chronic itch-associated AD and patients
having chronic pain associated with PHN. Skin punch biopsies
5 mm in diameter taken from forearms of 3 patients diagnosed
with AD in the biopsy locations were purchased from a commercial
supplier (Astrand Ltd) (Table 1). Two biopsies were obtained from
patient AD 1: one from a nondiseased (“normal”) skin site and one
from a site on the forearm afflicted with AD. The other 2 patients
(AD 2 and AD 3) were each the source of a single biopsy; one from
an AD-afflicted site on the arm (AD 2) and one from an AD-afflicted
site on the back (AD 3). These biopsies were flash frozen in
isopentane chilled with liquid nitrogen, stored at 280˚C, and
shipped on dry ice by overnight courier for histological processing.
Following procedures approved by the Albany Medical College
Institutional Review Board, four 3-mm punch biopsies of back
skin were obtained from each of the 5 “normal” subjects (Nor 1–5)
with no known neuropathic or dermatopathic conditions and
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Table 1
Description of specimens from human skin biopsies.
Patient #

Sex

Age

Biopsy site

Biopsy 1

Biopsy 2

AD 1

M

77

Forearm

AD

Normal

AD 2

M

79

Forearm

AD

n/a

AD 3

F

43

Back

AD

n/a

Normal 1

M

50

Back

Left

Right

Normal 2

M

68

Back

Left

Right

Normal 3

M

72

Back

Left

Right

Normal 4

M

79

Back

Left

Right

Normal 5

M

80

Back

Left

Right

PHN 1

M

50

Back

Ipsi

Contra

PHN 2

M

70

Back

Ipsi

Contra

PHN 3

M

80

Back

Ipsi

Contra

PHN 4

M

81

Back

Ipsi

Contra

PHN 5

M

86

Back

Ipsi

Contra

AD, atopic dermatitis; PHN, postherpetic neuralgia.

each of the 5 patients (PHN 1–5) who resolved with PHN after
being afflicted with acute herpes zoster in a unilateral thoracic
dermatome (Table 1). Each PHN patient had a pain rating .3/10
on a visual analog scale. Two closely spaced biopsies were taken
from each mirror-image location on the right and left dermatomes
of the normal subjects, and 2 each from the PHN-afflicted
dermatome (ipsilateral) and from the mirror image locations on the
unafflicted dermatome (contralateral). One biopsy from each
collection location of each person was flash frozen in isopentane
chilled with liquid nitrogen and stored at 280˚C until sectioning.
The second biopsy from each location was fixed by immersion for
4 hours in 4% PFA in 0.1M PBS at 4˚C, pH 7.4. After fixation, the
PFA immersion-fixed biopsies were rinsed in copious cold PBS
and stored under refrigeration for histological processing. Before
freezing and cutting, the immersion-fixed biopsies were cryoprotected by infiltration with 30% sucrose (Sigma-Aldrich) overnight.
The normal vs diseased status of the biopsies was blinded
before processing and remained so during subsequent analyses.
All biopsies were sectioned at 14 mm thicknesses using cryostat at
220˚C in a plane perpendicular to the epidermis. For the flashfrozen biopsies, sections were thaw-mounted onto slides (maintained in the cryostat during cutting) by briefly touching the
underside of the slide with a finger tip. The slides were stored at 2
80˚C until further processing. Various methods of fixing the flashfrozen sections on slide were assessed, with 10-minute immersion
in 220˚C acetone providing IL results most similar to that of PFAfixed skin. Sections from PFA-fixed biopsies were thaw-mounted
onto room temperature slides and air-dried overnight until further
processing. Sections from all biopsies were mounted in serial
order, rotated across 20 slides such that 10 slides had
approximately 15 sections spaced at equal intervals through each
biopsy and 10 others had 3 sections spaced at equal intervals
through each biopsy. The slides were then used for different single
and double IL combinations to develop a comprehensive immunocytochemical and morphological profile of each biopsy.
For IL, all slides were preincubated for 30 minutes at room
temperature in PBS with 1% BSA. Incubations with primary
antibodies diluted in PBS-BSA were conducted overnight under
refrigeration, followed by 30-minute rinse in PBS and incubation
with secondary antibodies diluted in PBS-BSA at room temperature for 2 hours. The slides were rinsed in PBS and coverslipped
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with 95% glycerin in PBS. Unused slides were hydrated with PBS
and archived under glycerin-mounted coverslips at 220˚C for
future use with other biomarkers or repeat assessments as
needed. For this study, sections were processed with doublelabel combinations of the guinea pig anti–GluA4N, rabbit anti–
GluA4C, rabbit anti–Loricrin, and rabbit anti–TSLP as described.
Secondary antibodies used were donkey anti–guinea pig IgG or
donkey anti–rabbit IgG conjugated to Cy3 or Alexa 488. Sections
were counterstained with DAPI to label cell nuclei. Several slides
from these biopsies had previously been analyzed to assess
characteristics of the innervation and other biomarkers among the
epidermal keratinocytes which are not the subject of this study.
Epifluorescence images from the human biopsy samples and
the organotypic epidermal cultures (see below) were captured
using an Olympus BX51-WI microscope system equipped with
a Hamamatsu ER high-speed camera, controlled via Neurolucida
software (MBF Biosciences, Essex, VT) operating Win7 on
a stand-alone PC. For all experiments, optimal camera capture
settings were determined for each immunolabel before analysis,
and the identical camera settings were used to capture all images
of a given immunolabel across each experimental group.
2.9. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analyses were conducted
to confirm the results of the GluA4 IL analyses. The RNAscope
Multiplex Fluorescent Assay (Advanced Cell Diagnostics [ACD],
Hayward, CA) was performed using target probes to GRIA4 on
alternating sections of the PFA-fixed human skin biopsies.
Unfortunately, no alternating sections of the flash-frozen biopsies
were available because of previous use in optimizing postsectioning
fixation protocols for IL. The tissue sections were treated with
pretreatment solutions of proprietary composition (ACD) and were
used according to the manufacturer’s instructions. The slides were
washed with 0.1M PBS in a Tissue-Tek slide rack for 5 minutes to
remove OCT. The tissues were pretreated sequentially with 13
Target Retrieval solution (or pretreatment solution 2) in a beaker at
99˚C to 100˚C for 5 minutes and with pretreatment solution 3
(protease digestion) 30 minutes at room temperature. The slides
were then incubated with a custom-synthesized GRIA4 RNAscope
probe for 2 hours at 40˚C, followed by amplifying hybridization
processes. Tissue sections were then incubated with Amp1
(preamplifier) for 30 minutes at 40˚C, Amp2 (background reducer)
for 15 minutes at 40˚C, Amp3 (amplifier) for 30 minutes at 40˚C, and
Amp4 (label probe) for 15 minutes at 40˚C in a HybEZ oven (ACD).
After each hybridization step, samples were rinsed in 13 wash
buffer twice for 2 minutes each at room temperature. The GRIA4
RNAscope human probe contains 1067 base pairs (NM_000829.3,
ACD#300031). The slides were stained with DAPI for 30 seconds at
room temperature and were then mounted with mounting medium
for fluorescence (Vectashield; Vector laboratories, Burlingame, CA).
Sections were imaged with a Leica scanning confocal microscope
(Leica Microsystems Inc.) using an LD C-Apochromat 403 oil lens.
Z stacks were performed on all sections using pinhole settings that
resulted in 1.0-mm thick optical sections.
2.10. Quantification of GluA4 and GRIA4 expression in
epidermal keratinocytes
For the back skin biopsies of the 5 PHN patients and 5 normal
subjects, the relative intensity of GluA4-IL in epidermal keratinocytes was assessed using Photoshop CS2 software (Adobe
Systems, San Jose, CA) to calculate average pixel intensity at 8
equally spaced locations along the epidermis in each of the 3

sections spaced 1 quarter, half, and 3 quarters through the
biopsy (ie, 24 samples or biopsy). A 2-tailed, paired t test was
used to compare these 24 averages for the left and right biopsies
from each normal subject and the ipsilateral and contralateral
biopsies from each PHN patient.
2.11. Organotypic epidermal cultures
The StrataTest (Stratatech Inc, Madison, WI) 3D organotypic human
skin cultures are composed of an epidermis and a dermis,
manufactured using proprietary normal immortal keratinocytes
(NIKS) and human dermal fibroblasts.2 The StrataTest 24 3 1 cm
well-test plate provided fully stratified, multilayered human skin
cultures in every well, and was shipped in gelatinized suspension
media. On arrival, single 3D cultures were transferred to 6-well plates
and placed into 1 mL of normal maintenance media for 24 hours to
reconstitute viability, as per the manufacturer’s instructions. Control
cultures were then fed everyday for 3 consecutive days with normal
maintenance media. Test cultures were fed on day 1 with normal
maintenance media. On day 2, test cultures were fed with
maintenance media that was supplemented with either 1 mM
Capsaicin (Cap; Caymen Chemical, Ann Arbor, MI) in dimethyl
sulfoxide or 1% (vol/vol) of complete Freund adjuvant (CFA; supplied
as a 1 mg/mL suspension in nonmetabolizable oils [paraffin oil and
mannide monooleate; Sigma-Aldrich]). The concentrations of the
test substances carrier media (dimethyl sulfoxide or mineral oil) were
considered negligible once the capsaicin or CFA were dissolved into
the culture media. Test cultures had the test media replaced again
on day 3 to create a 48-hour treatment period. On day 4, all cultures
were rinsed 33 with warm PBS, fixed for 2 hour with ice-cold 4%
PFA, rinsed and cryoprotected overnight in 30% sucrose at 4˚C.
Subsequently, cultures were frozen and cryostat sectioned perpendicular to the epidermal surface at 14 mm onto glass microscope
slides for IL procedures as described above for skin biopsies.

3. Results
3.1. Mouse keratinocytes express GluA4 AMPAR subunits
AMPAR subunit IL was first investigated in the glabrous skin
epidermis of mouse hind paws. We found prominent GluA4-IL in
suprabasal keratinocytes (GluA4C, see Methods) at the level of the
stratum spinosum (SS, Fig. 1A), where the IL puncta decorated cell
boundaries of the keratinocytes. To examine whether other AMPAR
subunits were also expressed, we conducted additional IL;
however, antibodies to the GluA1, A2, or A3 AMPAR subunits
failed to detect a reliable signal. Additional labeling evaluating the
expression of GluA4C in hairy skin from the dorsum of the mouse
revealed GluA4-IL in the bulge of the hair follicle (Fig. 1B, arrow),
and intermittently in the interfollicular epidermis (Fig. 1C, white
arrow). Hair bulge keratinocyte stem cells express the transmembrane protein CD34,5 and colabeling of GluA4 and CD34 was
confirmed (Fig. 1C), although GluA4-IL was more apparent in the
inner layer of the bulge cells. Negative controls in the absence of
primary antibody in mouse glabrous and hairy skin were also run to
test the specificity of the GluA4 labeling (Supplementary Figure 1A,
available online at http://links.lww.com/PR9/A1).
To corroborate GluA4 expression in CD34(1) keratinocytes, Gria4
RT-PCR was performed on FACS-purified CD34(1) keratinocytes.
Bulge keratinocytes were gated based on their expression of a6
integrin and CD34, and the relative absence of Sca-1 (Fig. 1D), as
previously reported.29 FACS gating of a6(1)/CD34(1)/Sca-1(2) cells
revealed that these cells comprised 13% of the live keratinocyte
population (Fig. 1D). Gria4 RT-PCR of a6(1)/CD34(1)/Sca-1(2)
keratinocytes was conducted using primers spanning exon 18 to
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Figure 1. Mouse keratinocytes express the GluA4 AMPAR subunit. (A) In glabrous skin, confocal imaging revealed prominent GluA4-IL consistently among the
suprabasal differentiating keratinocytes in SS of the epidermis. The labeling was more variable and generally less intense among the keratinocytes in SB and was
consistently weak among the superficial differentiated keratinocytes of SG. Dotted line indicates dermal or epidermal basement membrane boundary. (B) In hairy
skin, GluA4-IL (arrows) was observed in the bulge of the hair follicle (pink arrow), and intermittently in SB of the interfollicular epidermis (white arrow). GluA4-IL
appeared more prominent in the inner layer of the bulge cells. (C) Colocalization of GluA4 (green) with CD34 (red), a membrane marker of hair follicle bulge stem
cells. Scale bar 5 20 mm. (D) GluA4-positive cells were collected as a61/CD341/Sca-12 cells using FACS. (E) Gria4 RT-PCR product of expected size (288 bp)
was observed in CD341 cells, while unsorted keratinocytes produced 2 RT-PCR bands. Gapdh and CD34 primers were included as positive controls. Asterisks
represent 600 bp of a 100 bp ladder. Red square in image: Gria4 ex18-19, 288 bp. FACS, fluorescence-activated cell sorting; FITC, fluorescein isothiocyanate; IL,
immunolabeling; PE, phycoerythrin; RT-PCR, reverse transcription PCR; SB, stratum basalis; SC, stratum corneum; SG, stratum granulosum; SS, stratum
spinosum.

exon 19 of Gria4 (Gria4 ex18-19). CD34 and Gapdh were amplified
as positive controls (Fig. 1E). Gria4 ex18-19 primers yielded products
of the expected size (Fig. 1E, red box, Gria4 ex18-19: 288bp), and
the identity of this product as amplified Gria4 ex18-19 was
sequence-verified (Supplementary Figure 2, available online at
http://links.lww.com/PR9/A1). The unsorted keratinocyte RNA produced 2 Gria4 RT-PCR bands (Fig. 1E). These results confirmed the
expression of Gria4/GluA4 mRNA in mouse CD34(1) keratinocytes.
3.2. Newborn and adult human keratinocytes express GluA4
AMPAR subunits
To evaluate potential conservation of the epidermal keratinocyte
expression of GluA4, GluA4-IL was first investigated in sections of
human newborn foreskin. GluA4-IL (GluA4N, see Methods) was

observed through all the layers of the epidermis (Fig. 2A–D),
prominently in the suprabasal layers (Fig. 2C) and weakly in the
stratum basalis (SB, Fig. 2D). GluA4-IL was particularly concentrated among the keratinocytes of stratum granulosum (SG)
which were colabeled with Loricrin, a protein whose expression is
normally restricted to these terminally differentiated keratinocytes9 (Fig. 2A–C). Both GluA4-IL and Loricrin-IL appeared to be
membrane-localized (Fig. 2C). Expression of GRIA4 transcript in
human newborn foreskin was also investigated by FISH.
Figure 3A and B demonstrates that the GRIA4 RNAscope
human probe targeting base pairs 606–1673 showed robust
signal among presumptive midlevel SS keratinocytes of the
epidermis. The GRIA4 transcript expression among neonatal
keratinocytes matches the expression observed for GluA4-IL, as
seen in Figure 2A–D.
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Figure 2. GluA4-IL is observed in epidermal keratinocytes from human newborn foreskin. GluA4-IL was present on keratinocytes in all the strata of the epidermis
(A–D), especially in an apparent membranous localization among the suprabasal keratinocytes (C) and weakly and more intracellularly in SB (D). GluA4-IL was
particularly concentrated on the keratinocytes of SG that colabel for Loricrin. Some residual GluA4-IL and Loricrin-IL are present on the dead keratinocytes in SC.
DAPI was used to label the nuclei (blue), and the dotted lines indicate the epidermal (E)–dermal (D) boundary (insets from panel B overlay). Scale 5 20 mm. IL,
immunolabeling; SB, stratum basalis; SC, stratum corneum; SG, stratum granulosum; SS, stratum spinosum.
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We then examined GluA4 expression in sections of punch
biopsies of back skin from healthy adult volunteers (Fig. 3C),
normal forearm skin from a patient with AD in other forearm
locations, and back skin of patients with PHN taken contralateral to
the dermatome injured by acute herpes zoster (Figs. 4 and 5).
GluA4-IL was evaluated using 2 different GluA4 antibodies, GluA4N
and GluA4C (see Methods). In the epidermis of normal adult back
skin, GluA4-IL was observed among all epidermal vital keratinocyte
layers, with most robust expression typically observed in outer SS
and SG (Fig. 3C; Supplementary Figure 3, available online at http://
links.lww.com/PR9/A1). As well, we also assessed the specificity of
GluA4-IL in human biopsies from control volunteers (see Supplementary Figure 1B, available online at http://links.lww.com/PR9/
A1). Furthermore, in situ hybridization on alternating sections from
the same biopsies used to perform the IL confirmed expression of
GRIA4 transcript in epidermal keratinocytes (Fig. 3B). In normal
forearm epidermis, GluA4-IL increased from SB to SG (Fig. 4A, C).
GluA4C-IL was mostly observed at or near the keratinocyte
membrane (Fig. 4C), whereas GluA4N-IL appeared throughout the
cytoplasm (Figs. 4D, 5A, B, E, F, H; Supplementary Figure 3,
available online at http://links.lww.com/PR9/A1). In some specimens, both GluA4 antibodies produced labeling closely affiliated
with the nuclei of keratinocytes in SS and SB (Fig. 5D, H). Together,
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these findings support a broad pattern of GluA4 protein expression
in the adult epidermis.
In normal skin, Loricrin-IL was restricted to the most superficial
keratinocytes of SG, overlapping with the outermost distribution
of GluA4 labeling (Figs. 4D, 5E, F, H). GluA4-IL and Loricrin-IL
were extremely faint among the cornified, enucleated keratinocytes of normal stratum corneum (SC) (Figs. 4D, 5E, F, H).
Loricrin-IL was typically detected at or near the membranes of
keratinocytes of healthy forearm glabrous skin (Fig. 4D), but
exhibited cytoplasmic distribution in keratinocytes from skin of
the back (Fig. 5F, H). In parallel with GluA4 and Loricrin, we also
examined expression of TSLP, a cytokine implicated in AD.15,50 In
both forearm and back skin epidermis of healthy skin, TSLP-IL
expression coincided with GluA4-IL, with a similar expression
gradient increasing from deep to superficial, with peak intensity in
SG (Figs. 4A, 5A, B, D).
3.3. GluA4 expression in epidermal keratinocytes is altered in
human dermatopathies associated with
sensory abnormalities
Given our previous work on the altered expression of neurosignaling molecules in neuropathic pain conditions in humans,25,52

Figure 3. Expression of GluA4 protein and GRIA4 transcript in human skin. Fluorescence in situ hybridization demonstrates GRIA4 mRNA expression among the
epidermal keratinocytes of among keratinocytes of neonatal foreskin (A), and adult back skin biopsies (B). These results mirror the GluA4 protein expression in
human back skin biopsies (C) and neonatal foreskin (Fig. 2). Representative 340 confocal images for in situ hybridization detection of GRIA4 mRNA (green) are
shown separate and merged with DAPI-labeled nuclei (blue). GRIA4 mRNA was observed in all the strata of the epidermis, but appeared particularly strong among
SS or SG. Scale bar 5 20 mm. SG, stratum granulosum; SS, stratum spinosum. Solid lines represent SC, dotted lines represent SB.
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Figure 4. GluA4 expression is increased in skin biopsies from AD patients. Immunofluorescence labeling for GluA4, TSLP, and Loricrin among skin biopsies from
a normal skin site and AD site from patient AD 1, and AD sites from patients AD 2 and AD 3. The sections are counterstained with DAPI to reveal cell nuclei. The
dashed line indicates the location of the SB basement membrane dermal or epidermal junction; the solid line indicates the superficial border of SG which is
normally the most superficial layer of vital nucleated keratinocytes; and the dotted line indicates zones of live keratinocytes that appear atopically located in the SC
which is normally only composed of enucleated dead keratinocytes. Triple labeling for GluA4N (red), TSLP (green), and DAPI (blue) is shown in normal and AD skin.
(A) In normal unaffected skin from patient AD 1, GluA4N-IL appears concentrated on the membrane and to a lesser degree in the cytoplasm of the most superficial
keratinocytes of SG. Perinuclear GluA4N-IL is observed among deeper layer keratinocytes. TSLP-IL parallels the distribution of GluA4N-IL but is concentrated in
the cytoplasm of the most superficial keratinocytes of SG with lower intensity expression in the cytoplasm of deeper keratinocytes. GluA4N-IL and TSLP-IL are faint
or absent in SC. (B) In the AD biopsy from patient AD 1, GluA4N-IL is barely detectable among the live keratinocytes, but is intensely expressed in SC among the
atopic live keratinocytes. By contrast, TSLP-IL is intensely expressed in the cytoplasm of keratinocytes throughout SG and most of SS, as well as in SC
parakeratosis. (C) GluA4C-IL in unaffected control skin from AD 1 demonstrates expression among all the vital epidermal strata with higher expression among the
SG keratinocytes, without evidence of perinuclear labeling. In the AD biopsy from patient AD 1, GluA4C-IL (E) is virtually identical to that of GluA4N-IL (B),
particularly faint among the vital keratinocytes, but intense among the atopic parakeratosis. Triple labeling for GluA4N (green), Loricrin (red), DAPI (blue) in normal
(D) and AD skin (F) revealed that in normal unaffected skin, Loricrin-IL is restricted to the most superficial keratinocytes of SG where there is the most intense
expression of GluA4N-IL. In the AD biopsy, Loricrin-IL is expanded in SG and is also intensely expressed in SC. GluA4C-IL in the AD biopsies from patients AD 2
and AD 3 reveals that GluA4C-IL in patient AD 2 (G) has a membrane distribution among keratinocytes in most layers, much like that observed with the GluA4C-IL
in the normal biopsy (C) but is also intensely expressed in SC. (H) The GluA4C-IL in patient AD 3 is mostly perinuclear among nucleated keratinocytes in SB, SS,
and SG, and is also intensely expressed in SC. Scale bar 5 100 mm. AD, atopic dermatitis; IL, immunolabeling; SB, stratum basalis; SC, stratum corneum; SG,
stratum granulosum; SS, stratum spinosum; TSLP, thymic stromal lymphopoietin.
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Figure 5. GluA4 expression is decreased in skin biopsies from PHN patients. (A) Immunofluorescence labeling for GluA4N, TSLP, and Loricrin as seen in 14-mm
thick sections of PFA immersion-fixed back skin biopsies from normal human subjects and PHN patients. GluA4N is expressed on keratinocytes across SB, SS,
and SG, but not in SC. In normal subjects, the intensity of GluA4N-IL is comparable in mirror-image biopsies from the left and right side (left panels in A, B and E, F).
By contrast, GluA4N-IL intensity was consistently lower in the biopsies from PHN skin sites (ipsi) than in mirror-image contralateral unafflicted skin (contra, left
panels C, D and G, H). (A–D) Triple labeling for GluA4N (red), TSLP (green), and DAPI (blue) in normal (A, B) and PHN skin (C, D). The TSLP-IL is expressed on
keratinocytes throughout SB, SS, and appearing slightly more intense among the superficial keratinocytes in SG. The TSLP-IL appears to be slightly higher and
more uniformly expressed among the keratinocytes in the PHN skin. (E–G) Triple labeling for GluA4N (red), Loricrin (green), and DAPI (blue) in normal (A, B) and
PHN skin (C, D). Loricrin-IL is restricted to the most superficial keratinocytes of SG in normal skin and in both the PHN and mirror-image skin. (I, J) GRIA4 mRNA
expression in the ipsilateral PHN-afflicted and contralateral unafflicted dermatomes of patients PHN 1 and PHN 5. Scale bar 5 100 mm. IL, immunolabeling; PFA,
paraformaldehyde; PHN, postherpetic neuralgia; SB, stratum basalis; SC, stratum corneum; SG, stratum granulosum; SS, stratum spinosum; TSLP, thymic
stromal lymphopoietin.

and our new evidence of GluA4 expression in human keratinocytes,
we investigated GluA4-IL in the epidermis of patients with AD and
PHN. Atopic dermatitis is the most common chronic inflammatory
skin disease and manifests as overt rashes and clinically
problematic itch that is not completely understood.31,35 Postherpetic neuralgia is a neuropathic pain condition occurring as a result
of reactivation of varicella zoster virus, with initial nerve damage and
rash, often followed by skin healing but recurrent severe allodynia
and hyperalgesia at the rash site. In PHN, pathologies of epidermal
nerve endings and keratinocytes remain long after remission of the
initial rash associated with the primary zoster reactivation.25,30
Atopic dermatitis skin was compared with healthy skin within the
same patient, and affected PHN skin was compared with

unaffected contralateral skin from the same patients as well as
with the skin from healthy patients.
Consistent with a previously known characteristic of AD,45 DAPI
staining of sections from the biopsies from the afflicted sites in all 3
AD patients revealed plaques of nucleated keratinocytes in SC,
referred to as parakeratosis6 (dotted outlines, Fig. 4B, F–H).
Importantly, GluA4, Loricrin, and TSLP showed a distinct
distribution pattern in all 3 biopsies from the AD patients.
Intense GluA4, TSLP, and Loricrin-IL was present in SC of AD
patients, particularly in the plaques where it far exceeded
saturation at camera settings optimized for capture of GluA4 in
biopsies of normal skin (Fig. 4B, F). GluA4-IL varied among the
vital keratinocyte strata (SB, SS, and SG) of the biopsies from
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http://links.lww.com/PR9/A1). The GluA4-IL from biopsies of
PHN patients taken from the contralateral sites demonstrated
labeling comparable with that of the normal specimens
(Figs. 5D, H, 6, Supplementary Figure 3, available online at
http://links.lww.com/PR9/A1). TSLP-IL and Loricrin-IL were
similar among the PHN patients and control subjects, including
those from PHN-afflicted dermatomes (Fig. 5A–H).
3.4. GluA4 expression in organotypic keratinocyte cultures is
modulated by algogenic substances

Figure 6. Quantification of the reduction in GluA4 levels in biopsies from
postherpetic neuralgia (PHN) patients. Relative GluA4 immunolabel luminescence among epidermal keratinocytes of back skin biopsies taken from mirrorimage locations in the left and right dermatomes of 5 normal subjects and
PHN-afflicted (ipsilateral) dermatomes and unafflicted contralateral dermatomes of 5 PHN patients. **P , 0.01, ***P , 0.001.

the 3 patients. Patient AD 1 had weak GluA4-IL across all the
strata (Fig. 4E), while patient AD 2 had intense GluA4-IL among
all the strata (Fig. 4G), whereas patient AD 3 had weaker
membranous and stronger nuclear-like GluA4-IL scattered
across all the strata (Fig. 4H). Compared with biopsies of
normal skin locations, TSLP-IL in all 3 AD specimens was
particularly robust within and near the membrane, as well as in
the cytoplasm of keratinocytes in SS and SG (Fig. 4A, B for
patient AD 1, not shown for patients AD 2 and AD 3). TSLP-IL
remained faint in SB. Finally, Loricrin-IL was intense among SG
keratinocytes, but was also expressed among SS keratinocytes,
which is not observed in the control skin (Fig. 4D, F for patient
AD 1, not shown for patients AD 2 and AD 3).
GluA4-IL was also altered in skin of patients with PHN. We
compared the relative intensity and distribution of GluA4-IL from
dermatome-matched ipsilateral and contralateral biopsies from
PHN patients and found that GluA4-IL from the afflicted sites was
significantly diminished compared with dermatome-matched
contralateral biopsy specimens in 4 of the 5 PHN patients
(Figs. 5C, D, G, H, 6; Supplementary Figure 3, available online at
http://links.lww.com/PR9/A1). These findings were confirmed
using in situ hybridization, which also showed significantly lower
GRIA4 transcript expression in the ipsilateral PHN compared with
contralateral unafflicted epidermal keratinocytes within subjects
(P . 0.005, paired t test) (Fig. 5I, J). The relative intensity and
distribution of GluA4-IL were similar between the left and right
dermatome-matched biopsies in all the 5 healthy subjects
(Figs. 5A, B, E, F, 6; Supplementary Figure 3, available online at

Glutamate signaling in keratinocytes is known to promote barrier
functions, particularly mediated through NMDA receptors;
however, a role for AMPAR in keratinocyte signaling has not
been strongly established.14,15 AMPARs have been implicated in
nociceptor hypersensitivity associated with chronic inflammatory
pain mechanisms, and the use of peripheral AMPAR antagonists
for inflammatory pain has been suggested previously.16 Keratinocyte signaling contributes to normal functioning and pathogenic pain mechanisms associated with inflammatory skin
conditions; therefore, we adapted a standard model of inflammatory pain production from an in vivo setting CFA, as well as
a known activator of keratinocytes (capsaicin) as test agents in
human organotypic keratinocyte cultures to determine if these
algogenic substances also affected the keratinocyte expression
of GluA4.
To best characterize the regulation of keratinocyte GluA4
expression, full-thickness epidermal cultures are essential, as
monolayer keratinocytes do not fully differentiate into the
signaling patterns observed in vivo. Therefore, we made use of
organotypic cultures of fully differentiated and stratified epidermis
generated from a stable immortalized line of human keratinocytes
(Stratatech Inc, Madison, WI) and examined GluA4 expression by
immunofluorescence and in situ hybridization after stimulation. As
shown in Figure 7A, both GluA4 protein and GRIA4 mRNA were
detected throughout the live layers of untreated keratinocytes.
Capsaicin, a pungent chemical that binds the polymodal TRPV1
ion channel, evokes pain behaviors and can produce itch, has
been reported to stimulate mediator release from isolated human
keratinocytes.34 Treatment of the organotypic stratified keratinocyte cultures with capsaicin nearly eliminated GluA4 protein and
GRIA4 transcript detection among the suprabasal keratinocytes
(Fig. 7B). Similarly, treatment of the cultures with CFA,
a mycobacterial extract that induces pain behaviors and alters
keratinocyte neurochemistry in vivo25 likely through toll-like
receptor activation, also reduced the detection of both the GluA4
protein and GRIA4 transcript in the cultures (Fig. 7C).

4. Discussion
Much evidence over the past 15 years has now firmly established
sensory signaling between epidermal keratinocytes and small
caliber axons of primary afferents.4,13,41 Here, we present the
observation of GluA4 AMPAR in mouse and human keratinocytes.
Reverse transcription PCR confirmed Gria4 mRNA expression in
FACS-isolated mouse keratinocytes. In addition, in situ hybridization conducted in skin biopsies from human control volunteers
confirmed GRIA4 mRNA expression in epidermal keratinocytes.
GluA4 expression was also explored in the epidermis of patients
with AD or PHN. Intense GluA4-IL expression was present in the
parakeratosis plaques in SC of biopsies from afflicted skin areas in
patients with AD, and this increase coincided with an intense TSLP
expression. By contrast, GluA4-IL and mRNA were diminished in
hypersensitive skin areas from PHN patients. In organotypic
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Figure 7. Organotypic cultures. GluA4-IL and GRIA4 mRNA expression with a DAPI counterstain in alternating sections from organotypic epidermal cultures
exposed to (A) normal medium; (B) medium containing 1 micromolar capsaicin; and (C) medium containing 1% CFA. Both GluA4-IL and GRIA4 mRNA are severely
depleted in the treated cultures. CFA, complete Freund adjuvant.

cultures, capsaicin, and CFA, 2 proinflammatory algogenic agents
typically used in experimental pain models triggered a decrease in
GluA4-IL and mRNA expression. Thus, GluA4 keratinocyte
expression was differentially modulated under naturally occurring
specific disease conditions involving epidermal pathology and
sensory abnormalities.
Our studies of the mouse epidermis showed keratinocyte
GluA4-IL in distinct locations (Fig. 1A–C), suggesting that
multiple sources of glutamate may exist for the GluA4 AMPAR.
Genever et al.20 documented expression of the high-affinity
glutamate transporter EAAT2 in differentiating suprabasal keratinocyte layers, whereas a different transporter EAAT3 was
expressed in the SB, which contains proliferative keratinocytes.
Although keratinocytes themselves are capable of producing and
releasing L-glutamate,17 primary afferent neurons represent
another potential source of glutamate.12 Indeed, a recent study
by Woo et al.51 showed that peripheral nerve endings of primary
afferents innervating pelage hairs have vGluT2 and play a role in
the organization of the piloneural collar. Woo et al. actively sought
cells expressing metabotropic or ionotropic glutamate receptors

near vGluT21 nerve endings. Our findings demonstrating GluA4
expression in keratinocytes from the bulge of the hair follicle raise
the possibility that these primary afferents modulate keratinocyte
function through AMPAR.
GRIA4 mRNA expression has been reported previously in human
skin biopsy specimens,47 although the identity of the cell type
expressing GRIA4 remained obscure. Based on our GluA4-IL in hair
follicle bulge stem cells,5 we isolated a6(1)/CD34(1)/Sca-1(2) cells
and performed RT-PCR and Sanger sequencing, thereby
confirming that these cells express Gria4/GluA4. GluA4-IL was
prominently observed in the inner layer of the bulge, which
includes proliferating descendants of the outer root sheath stem
cells. The existence of Ca21 permeable AMPAR subunits in the
inner layer of the bulge suggests that AMPAR could participate
in Ca21-induced differentiation of keratinocytes.23 However,
unsorted keratinocyte preparations yielded at least one other
RT-PCR product (Fig. 1E). The sequence identity of this
additional band was not pursued; however, it is likely that
a splice variant of Gria4 may also exist in other cells besides the
a6(1)/CD34(1)/Sca-1(2) keratinocytes. In this regard,
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neuronal Gria4 isoforms demonstrate diversity through alternative splicing46 and mRNA editing.7
Expression of GRIA4/GluA4-IL was also found in human
newborn foreskin samples. GluA4-IL in human foreskin sections
was weak in the SB, and gradually increased in differentiated
layers until reaching the highest intensity in the upper SG, then
faded out again in the SC. This expression pattern matches
approximately with the Ca21 gradient described in mammalian
epidermis,18 supporting the view of GluA4 playing a role in
keratinocyte differentiation. Comparing the GluA4-IL of mouse
and human skin samples, we note some similarities and some
differences between these results. For example, GluA4-IL of both
mouse and human skins showed membranous localization, was
generally lower in less differentiated keratinocytes (SB keratinocytes from glabrous skin, or CD34(1) cells in the case of mouse
hairy skin), and correlated with differentiation of keratinocytes
(suprabasal keratinocytes in glabrous skin, or cells from the inner
layer of the bulge of the hair follicle).26 However, in the mouse
glabrous skin, the more prominent GluA4-IL was found in the SS,
whereas in human GluA4-IL was more prominent in the SG.
Our study contributes to a growing body of evidence showing
that keratinocytes express a wide variety of molecules implicated
in cell proliferation and differentiation, but importantly also in
inflammatory and neurosignaling mechanisms.16,25,27,36 When
these neurotransmitters, neuromodulators, and cytokines stimulate their ionotropic and nonionotropic receptors, keratinocytes
release mediators that likely activate receptors on epidermal and
juxta-epidermal endings of sensory neurons implicated in nonnoxious mechanical and thermal sensation, as well as noxious
itch and nociception. These neurosignaling ligands or cognate
receptors expressed by keratinocytes include those typically
implicated in neuronal excitation or inhibition. The excitatory
receptors include TRP receptors, various G protein–coupled
receptors (GPCRs), purinergic ionotropic receptors, voltagegated ion channels, and their ligands including ATP, calcitonin
gene–related peptide, and glutamate.27,38 The inhibitory modulators include other GPCRs such as opioid, cannabinoid, and
P2Y receptors, as well as ligands including b-endorphin.14,28
Importantly, most of the various neurosignaling molecules
detected in the epidermis are expressed differentially among
the strata of keratinocytes.14,28 This suggests that sensory
transduction also involves autocrine or paracrine integration
among the keratinocytes, in addition to their action on the
innervation. Given the natural turnover and differentiation of
keratinocyte beginning from proliferation in SB, to extrusion of the
nucleus and displacement into SC, it is evident that the
differentially stratified signaling systems must be continually
reestablished in every new cohort of maturing keratinocytes.
To date, studies regarding cutaneous mechanisms of itch and
pain, especially chronic afflictions that are enigmatic and typically
untreatable, have focused on the potential varieties and
pathologies among epidermal and juxta-epidermal innervation,
resulting in considerable debate about whether itch and pain are
subserved by separate or confluent types of innervation.3,22,43
Several studies have indicated that chronic pain and itch
conditions also manifest striking pathologies among the expression patterns of the epidermal keratinocyte neurosignaling
molecules that may contribute to the changes in the density
and sensitivity of the IENFs.40,49 Because glutamate is the main
transmitter in small fibers, and is known to be important in
keratinocyte signaling, we investigated GluA4 expression among
the epidermal keratinocytes in 2 human afflictions with core
symptoms of intractable chronic itch (AD) and pain (PHN). In
addition to assessing GluA4-IL, we also examined IL for Loricrin

as an indicator of keratinocyte maturation,9 and TSLP, a keratinocyte produced cytokine which has been extensively implicated
in itch.49,50 Keratinocytes release TSLP in a calcium-dependent
manner, activating a subset of TRPA1(1) sensory neurons to
trigger itch responses.50 Because TSLP release involves Ca21
flux, and because AMPARs are ionotropic receptors that regulate
Ca21 permeability, we sought to assess the expression of GluA4IL under these pathological conditions.
Our results confirmed previous reports of substantial increases
in TSLP-IL expression in AD skin as compared with that in
nondiseased skin,50 especially as intense expression in the
plaques of parakeratosis in SC.45 This aberrant TSLP distribution
was paralleled by increased and expression of Loricrin-IL in
parakeratoses, indicative of accelerated keratinocyte differentiation. GluA4-IL was also consistently and intensely expressed in the
plaques of parakeratosis where an increase in intracellular [Ca21]
might contribute to pathological keratinocyte differentiation.
By contrast, in 4 of the 5 PHN patients, GluA4-IL was
significantly less intense among the epidermal keratinocytes in
the biopsies of PHN skin, as compared with GluA4-IL of biopsies
of mirror-image contralateral skin, and also when compared with
biopsies from normal subjects. Moreover, PHN was not
associated with any obvious change in TSLP or Loricrin
expression. This decrease in GluA4 may result in Ca21
dysregulation, which could contribute to aberrant neurosignaling
patterns observed in PHN skin.23
Interestingly, we also observed reductions in GluA4 expression
in organotypic stratified keratinocyte cultures, in response to
either CFA or capsaicin. Although both agents are able to
produce pain and hyperalgesia in intact skin, the consequences
of their direct activities on keratinocytes remain unclear. The
presence of GluA4 in epidermal keratinocytes is in addition to
several other neurosignaling molecules implicated in inhibitory
(analgesic) and excitatory (algesic) keratinocyte mechanisms
involved in autocrine or paracrine interactions and regulating
sensory fiber activity, and which contribute to itch and pain
pathways.4,14,21,25,28,32,42,44,52 Recently, the direct activation of
keratinocyte TRPV1 was shown to evoke aversive behavioral
responses;41 however, pain and itch could not be explicitly
distinguished in that study. Functionally, the alteration of GluA4
subunits among keratinocytes will alter Ca21 sensitivity and
signaling dynamics between cutaneous small fibers and IENF that
are pruritic or nociceptive. These potential GluA4-mediated
signaling differences may contribute to the normal distinctions
between itch and pain, as well as primary afferent hyperresponsivity under pathologic conditions.
In summary, this study provides evidence that GluA4containing AMPARs are expressed in epidermal keratinocytes
that human dermatopathies show alterations in the keratinocyte
expression levels of GluA4-containing AMPAR, and that algogenic substances can directly regulate the production of GluA4 in
keratinocytes. Our findings provide an impetus for future
functional studies of AMPAR channel activity and its biological
consequences in keratinocytes.
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